Rachel M. Layman

3.6k citations

105 papers · 2.0k indexed · h-index 23

Oncology top 2%
- HER2/EGFR in Cancer Research 31
- Cancer Treatment and Pharmacology 29
- Cancer-related Molecular Pathways 13
- PARP inhibition in cancer therapy 7
Cancer Research top 5%
- Breast Cancer Treatment Studies 35
Pulmonary and Respiratory Medicine top 5%
- Advanced Breast Cancer Therapies 48
Genetics top 5%
- Chronic Lymphocytic Leukemia Research 7
- BRCA gene mutations in cancer 7
Biological Psychiatry top 10%

Co-authors: Ewa Mrózek Charles L. Shapiro Janice K. Kiecolt‐Glaser William B. Malarkey Charles F. Emery Jeanette M. Bennett Ronald Glaser Rebecca Andridge
Cited by: Oncology Cancer Research Pulmonary and Respiratory Medicine
Journals: Journal of Clinical Oncology (21 papers)Cancer Research (15 papers)The Lancet Oncology (1 paper)
Partner nations: United States Italy South Korea

In The Last Decade

Rachel M. Layman

95 papers receiving 2.0k citations

Peers

Countries citing papers authored by Rachel M. Layman

Since Specialization

Citations

This map shows the geographic impact of Rachel M. Layman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachel M. Layman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachel M. Layman more than expected).

Fields of papers citing papers by Rachel M. Layman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachel M. Layman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachel M. Layman. The network helps show where Rachel M. Layman may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Rachel M. Layman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Rachel M. Layman Line = papers co-authored together Rachel M. Layman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Abstract PO3-20-06: TRUDI: A phase II study of neoadjuvant TRastuzumab derUxtecan and Durvalumab for stage III HER2-expressing Inflammatory breast cancer Cancer Research ·Paolo Tarantino,Samuel Niman,Antonio Giordano,Faina Nakhlis,Jennifer R. Bellon,Wendy A. Woodward,Azadeh Nasrazadani,Sadia Saleem,Anthony Lucci,Michelle K. DeMeo,Naoto T. Ueno,Sara M. Tolaney,Vicente Valero,Meredith M. Regan,Rachel M. Layman,Filipa Lynce	2024	2
2	Preliminary results from a phase 1 study of AC699, an orally bioavailable chimeric estrogen receptor degrader, in patients with advanced or metastatic breast cancer. Journal of Clinical Oncology ·Manish R. Patel,Rachel M. Layman,Michael Danso,David Cosgrove,Marjorie E. Zettler,Katherine C. Pehlivan,Erika Hamilton	2024	4
3	The multiomic tumor microenvironment landscape of invasive lobular carcinoma of the breast. Journal of Clinical Oncology ·Jason Mouabbi,Funda Meric‐Bernstam,Azadeh Nasrazadani,Blessie Elizabeth Nelson,Basim Salem,Владимир Кушнарев,Arina Tkachuk,Maria Sotova,Margarita Polyakova,О. Yu. Baranov,Polina Turova,Konstantin Chernyshov,Nikita Kotlov,Jessica H. Brown,Patrick Clayton,A. Sarachakov,Ekaterina Postovalova,Alexander Bagaev,Debashish Tripathy,Rachel M. Layman	2024	1
4	A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer. Journal of Clinical Oncology ·Toru Mukohara,Yeon Hee Park,David Sommerhalder,Kan Yonemori,Sung‐Bae Kim,Jee Hyun Kim,Hiroji Iwata,Toshinari Yamashita,Rachel M. Layman,Gun Min Kim,Seock‐Ah Im,Geoffrey J. Lindeman,Hope S. Rugo,Marlon Liyanage,Natasha Homji Mishra,Arnab K. Maity,Orlaith Bogg,Li Liu,M. Li,Patricia LoRusso	2024	2
5	Prolonging the lives of African–Americans with metastatic breast cancer by adding palbociclib to an aromatase inhibitor in routine clinical practice: a plain language summary of a real-world database study Future Oncology ·Hope S. Rugo,Xianchen Liu,Benjamin Li,Lynn McRoy,Connie Chen,Rachel M. Layman,Tiah Tomlin-Harris,Adam Brufsky	2024	1
6	Self-Reported Management of Inflammatory Breast Cancer Among the American Society of Breast Surgeons Membership: Consensus and Opportunities Annals of Surgical Oncology ·Alexa Glencer,Kerollos Nashat Wanis,Sydnee Brown,Anthony Lucci,Susie X. Sun,Taiwo Adesoye,Sarah M. DeSnyder,Rachel M. Layman,Wendy A. Woodward,Kelly K. Hunt,Mediget Teshome	2024	4
7	Real‐world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database International Journal of Cancer ·Hope S. Rugo,Xianchen Liu,Benjamin Li,Lynn McRoy,Connie Chen,Rachel M. Layman,Adam Brufsky	2023	9
8	223P Real-world effectiveness of palbociclib (Pal) plus an aromatase inhibitor (AI) vs AI alone in patients who have metastatic breast cancer (mBC) with lung or liver metastases ESMO Open ·Adam Brufsky,X. Liu,B. Li,Lynn McRoy,C. Chen,Rachel M. Layman,Hope S. Rugo	2023	1
9	204P Phase Ib study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: Updated results in treatment naïve patients ESMO Open ·Hope S. Rugo,Robert Wesolowski,Erica Stringer-Reasor,Hyo S. Han,Jennifer M. Specht,Claire Dees,Peter Kabos,Ulka N. Vaishampayan,Seth A. Wander,Janice Lu,Keerthi Gogineni,Alexander I. Spira,Anne F. Schott,Maysa Abu‐Khalaf,Sarah C. Mutka,Samuel Suzuki,Igor Gorbatchevsky,Rachel M. Layman	2023	1
10	Abstract P5-02-30: Histology-based survival outcomes in HR+/HER2- metastatic breast cancer treated with targeted therapies plus endocrine therapy based on HER2 expression Cancer Research ·Jason Mouabbi,Akshara Singareeka Raghavendra,Roland Bassett,Amy Hassan,Debu Tripathy,Rachel M. Layman	2023	2
11	Abstract P3-05-04: Absence of Lobular Carcinoma In Situ, a Poor Prognostic Marker in Invasive Lobular Carcinoma Cancer Research ·Jason Mouabbi,Akshara Singareeka Raghavendra,Matthias Christgen,Amy Hassan,Gabriel N. Hortobágyi,Debu Tripathy,Rachel M. Layman	2023	1
12	Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma The Oncologist ·Jason Mouabbi,Wei Qaio,Yu Shen,Akshara Singareeka Raghavendra,Debasish Tripathy,Rachel M. Layman	2023	3
13	Real-World Treatment Patterns and Outcomes of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis Clinical Breast Cancer ·Debra A. Patt,Xianchen Liu,Benjamin Li,Lynn McRoy,Rachel M. Layman,Adam Brufsky	2022	16
14	A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer Investigational New Drugs ·Sagar Sardesai,Mohamed Badawi,Ewa Mrózek,Evan Morgan,Mitch A. Phelps,Julie Stephens,Lai Wei,Mahmoud Kassem,Yonghua Ling,Maryam B. Lustberg,Daniel G. Stover,Nicole Williams,Rachel M. Layman,Raquel E. Reinbolt,Jeffrey VanDeusen,Mathew Cherian,Michael R. Grever,William E. Carson,Bhuvaneswari Ramaswamy,Robert Wesolowski	2020	24
15	176P Real-world tumour response of palbociclib plus letrozole vs letrozole for metastatic breast cancer in US clinical practices Annals of Oncology ·Adam Brufsky,X. Liu,B. Li,Lynn McRoy,Rachel M. Layman	2020	2
16	LBA1 Interim results of a phase I/Ib study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib (RIB) or alpelisib (ALP) in patients with ER+ breast cancer (BC) who had progressed after endocrine therapy (ET) Annals of Oncology ·Komal Jhaveri,Dejan Juric,Y-S Yap,Sara Cresta,Rachel M. Layman,François P. Duhoux,C. Terret,Serena De Vita,Nicole Kundamal,Wander He,Alejandro Balbin,Qing Sheng,Adam Crystal,Giuseppe Curigliano	2020	7
17	Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy Clinical Cancer Research ·William J. Gradishar,Denise A. Yardley,Rachel M. Layman,Joseph A. Sparano,Ellen Chuang,Donald W. Northfelt,Gary N. Schwartz,Hagop Youssoufian,Shande Tang,Ruslan D. Novosiadly,Amélie Forest,Tuan S. Nguyen,Jan Cosaert,Dmitri Grebennik,Paul Haluska	2015	54
18	Phase II Trial of Neoadjuvant Weekly Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Biweekly Bevacizumab Therapy in Women With Clinical Stage II or III HER2-Negative Breast Cancer Clinical Breast Cancer ·Ewa Mrózek,Rachel M. Layman,Bhuvaneswari Ramaswamy,Maryam B. Lustberg,Andrea Vecchione,Michael V. Knopp,Charles L. Shapiro	2014	29
19	Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors Clinical Cancer Research ·Anne F. Schott,Melissa D. Landis,Gabriela Dontu,Kent A. Griffith,Rachel M. Layman,Ian E. Krop,Lacey A. Paskett,Helen Wong,Lacey E. Dobrolecki,Michael T. Lewis,Amber M. Froehlich,Jaya Paranilam,Daniel F. Hayes,Max S. Wicha,Jenny C. Chang	2013	209
20	Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy Supportive Care in Cancer ·Candice M. Wenzell,Michael Berger,Marlo Blazer,Brooke Crawford,Niesha Griffith,Robert Wesolowski,Maryam B. Lustberg,Gary Phillips,Bhuvaneswari Ramaswamy,Ewa Mrózek,Joseph M. Flynn,Charles L. Shapiro,Rachel M. Layman	2013	19

About Rachel M. Layman

Rachel M. Layman is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 105 papers that have together received 2.0k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (48 papers), Breast Cancer Treatment Studies (35 papers), HER2/EGFR in Cancer Research (31 papers), Cancer Treatment and Pharmacology (29 papers), Cancer-related Molecular Pathways (13 papers), Chronic Lymphocytic Leukemia Research (7 papers), BRCA gene mutations in cancer (7 papers) and PARP inhibition in cancer therapy (7 papers). The work is most often cited by research in Oncology (1.2k citations), Cancer Research (518 citations) and Pulmonary and Respiratory Medicine (716 citations). Rachel M. Layman has collaborated with scholars based in United States, Italy and South Korea. Frequent co-authors include Ewa Mrózek, Charles L. Shapiro, Janice K. Kiecolt‐Glaser, William B. Malarkey, Charles F. Emery, Jeanette M. Bennett, Ronald Glaser, Rebecca Andridge, Juan Peng and Adam Brufsky. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact